SR-18292 is primarily used in biochemical and pharmaceutical research as a potent inhibitor of the enzyme SIRT1 (sirtuin 1). This compound modulates cellular processes linked to metabolism, aging, and stress response by blocking SIRT1-mediated deacetylation of target proteins such as PGC-1α and p53. Due to this inhibitory action, SR-18292 is employed in studies exploring cancer cell metabolism, where it disrupts the metabolic reprogramming that supports tumor growth. It has also been used to investigate insulin sensitivity and mitochondrial biogenesis in models of metabolic disease. Its ability to cross cell membranes makes it suitable for in vitro and in vivo studies, particularly in models of diabetes and neurodegeneration. Researchers use SR-18292 to probe the role of sirtuins in aging-related pathways and to assess potential therapeutic strategies for diseases involving dysregulated energy metabolism.